Screening Strategies in Drug Discovery – News and Features

Researchers at Weill Cornell used virtual screening to find small molecules targeting cancer checkpoints, showing promise as alternatives to monoclonal antibody treatments. The study identified compounds MG-T-19 and MG-V-53.

Researchers discovered that cordycepin, derived from the caterpillar fungus Cordyceps militaris, disrupts cancer cell growth by interfering with signaling pathways. The compound converts to cordycepin triphosphate within cells, mimicking ATP.

Technology Networks asked a selection of startups featured in the ELRIG Drug Discovery 2024 Breakthrough Zone how their technology might reshape the pharmaceutical industry and pave the way for the next generation of therapeutic discovery.

A study by EPFL shows how Pseudomonas aeruginosa manages the trade-off between biofilm formation for antibiotic protection and a mobile state to spread in the lungs.

We reached out to start-ups at ELRIG Drug Discovery 2024 to see how AI and bioengineering can be applied in biotech and drug discovery.

Technology Networks asked a selection of start-up companies at ELRIG Drug Discovery how their technology addresses key limitations in traditional disease models.

Technology Networks caught up with Dr. Anne Carpenter at ELRIG Drug Discovery 2024 to learn more about the Cell Painting assay and its impact on the pharmaceutical industry.

This article explores the revolution in new drug modalities and the challenges around effective data strategies to support AI efforts.

A new study has measured the toxicity of several types of PFAS, better known as “forever chemicals,” when mixed together in the environment and in the human body.

A UCLA team created a biobank of sarcoma organoids from 126 patients, enabling rapid drug screening. The organoids retained tumor characteristics, allowing identification of effective FDA-approved treatments for 59% of samples.